Rituximab Hit With FDA Warning on HBV Risk

Article

A black box warning has been added to the label of the commonly used anti-inflammatory drug rituximab warning that it may reactivate hepatitis B virus.

The US Food and Drug Administration has added a black box warning that ofatumumab (Arzerra) and rituximab (Rituxan) may reactivate hepatitis B virus (HBV).

Rituximab is used to treat rheumatoid arthritis and granulomatosis with polyangiitis, and both drugs are used for leukemia and lymphoma.

Patients should be screened for HBV with hepatitis B surface antigen and hepatitis B core antibody, says the notice.

If the result is positive:

1. Consult a hepatitis expert.

2. Monitor patients using these drugs for HBV.

3. If reactivated, stop and treat for HBV

Recent Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.